These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38604404)

  • 61. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
    Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
    Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inadequate inhaler technique, an everlasting problem, is associated with poor disease control - A cross sectional study.
    Padmanabhan M; Tamilarasu K; Rajaram M; Batmanabane G
    Adv Respir Med; 2019; 87(4):217-225. PubMed ID: 31476009
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High Prevalence of Suboptimal Peak Inspiratory Flow in Hospitalized Patients With COPD: A Real-world Study.
    Mahler DA; Demirel S; Hollander R; Gopalan G; Shaikh A; Mahle CD; Elder J; Morrison C
    Chronic Obstr Pulm Dis; 2022 Jul; 9(3):427-438. PubMed ID: 35788259
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A method of estimating inspiratory flow rate and volume from an inhaler using acoustic measurements.
    Holmes MS; Seheult JN; Geraghty C; D'Arcy S; O'Brien U; Crispino O'Connell G; Costello RW; Reilly RB
    Physiol Meas; 2013 Aug; 34(8):903-14. PubMed ID: 23892977
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhaled therapy in elderly COPD patients; time for re-evaluation?
    Jarvis S; Ind PW; Shiner RJ
    Age Ageing; 2007 Mar; 36(2):213-8. PubMed ID: 17267450
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.
    Malmberg LP; Rytilä P; Happonen P; Haahtela T
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():257-62. PubMed ID: 20714380
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Identifying critical inhalation technique errors in Dry Powder Inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multi-country cross-sectional observational PIFotal study.
    Kocks J; Bosnic-Anticevich S; van Cooten J; Correia de Sousa J; Cvetkovski B; Dekhuijzen R; Dijk L; Garcia Pardo M; Gardev A; Gawlik R; van der Ham I; Janse Y; Lavorini F; Maricoto T; Meijer J; Metz B; Price D; Roman Rodriguez M; Schuttel K; Stoker N; Tsiligianni I; Usmani O; Voorham J; Leving MT
    BMC Pulm Med; 2023 Aug; 23(1):302. PubMed ID: 37592263
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World Data.
    Anderson M; Collison K; Drummond MB; Hamilton M; Jain R; Martin N; Mularski RA; Thomas M; Zhu CQ; Ferguson GT
    Int J Chron Obstruct Pulmon Dis; 2021; 16():933-943. PubMed ID: 33883890
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults.
    Bronsky EA; Grossman J; Henis MJ; Gallo PP; Yegen U; Della Cioppa G; Kottakis J; Mehra S
    Curr Med Res Opin; 2004; 20(2):131-7. PubMed ID: 15006006
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Investigation of Appropriate Inhalation Technique for Mometasone Furoate Dry Powder Inhaler.
    Yokoyama H; Ito K; Mihashi H; Shiraishi Y; Takayanagi R; Yamada Y
    Biol Pharm Bull; 2016; 39(10):1576-1580. PubMed ID: 27725433
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Critical Inhaler Handling Error Is an Independent Risk Factor for Frequent Exacerbations of Chronic Obstructive Pulmonary Disease: Interim Results of a Single Center Prospective Study.
    Ahn JH; Chung JH; Shin KC; Choi EY; Jin HJ; Lee MS; Nam MJ; Lee KH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2767-2775. PubMed ID: 31819409
    [TBL] [Abstract][Full Text] [Related]  

  • 74. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes.
    Levy ML; Carroll W; Izquierdo Alonso JL; Keller C; Lavorini F; Lehtimäki L
    Adv Ther; 2019 Oct; 36(10):2547-2557. PubMed ID: 31478131
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Does mixing inhaler devices lead to unchecked inhaler technique errors in patients with COPD? Findings from the cross-sectional observational MISMATCH study.
    Dijk L; Kerkhof M; Driessen M; Gerritsma YH; Bosnic-Anticevich S; Correia-de-Sousa J; Dekhuijzen PNR; Leving M; Price DB; Tsiligianni I; Usmani O; Kerstjens HAM; Kocks JWH
    BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38135462
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [The variability of peak inspiratory flow (PIF) on valves imitating dry powder inhalers resistance during asthma and COPD exacerbations].
    Grabowski M; Barg W; Chmielowicz B; Kopeć A; Panaszek B
    Pneumonol Alergol Pol; 2007; 75(4):324-30. PubMed ID: 18080981
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
    Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of Suboptimal Peak Inspiratory Flow in Patients with Stable COPD.
    Represas-Represas C; Aballe-Santos L; Fernández-García A; Priegue-Carrera A; López-Campos JL; González-Montaos A; Botana-Rial M; Fernández-Villar A
    J Clin Med; 2020 Dec; 9(12):. PubMed ID: 33291438
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers.
    W H Kocks J; Wouters H; Bosnic-Anticevich S; van Cooten J; Correia de Sousa J; Cvetkovski B; Dekhuijzen R; Dijk L; Dvortsin E; Garcia Pardo M; Gardev A; Gawlik R; van Geer-Postmus I; van der Ham I; Harbers M; de la Hoz A; Janse Y; Kerkhof M; Lavorini F; Maricoto T; Meijer J; Metz B; Price D; Roman-Rodriguez M; Schuttel K; Stoker N; Tsiligianni I; Usmani O; Leving MT
    NPJ Prim Care Respir Med; 2022 May; 32(1):18. PubMed ID: 35618739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.